Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Initiator Pharma ASOSTO:INIT -6.42%24 EV-to-FCF is -3.86 as of Jul. 14, 2026. GuruFocus rates OSTO:INIT with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 335 Biotechnology companies, Initiator Pharma AS ranks worse than 298507.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Initiator Pharma AS's Enterprise Value is kr151.57 Mil.
Initiator Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-39.31 Mil. Therefore, Initiator Pharma AS's EV-to-FCF for today is -3.86.
The historical rank and industry rank for Initiator Pharma AS's EV-to-FCF or its related term are showing as below:
OSTO:INIT'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.15 Med: 0 Max: 0
Current: -4.15
OSTO:INIT's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs OSTO:INIT: -4.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Initiator Pharma AS (OSTO:INIT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Initiator Pharma AS's PE Ratio (TTM) for today is calculated as:
Initiator Pharma AS's share price for today is kr2.48.
Initiator Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.494.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Initiator Pharma AS EV-to-FCF Related Terms
Initiator Pharma AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Initiator Pharma AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:INIT vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Initiator Pharma AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Initiator Pharma AS EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Initiator Pharma AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Initiator Pharma AS's EV-to-FCF falls into.
Initiator Pharma AS's current Enterprise Value is kr151.57 Mil.
Initiator Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-39.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Initiator Pharma AS (OSTO:INIT) has a EV-to-FCF of -3.86 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Initiator Pharma AS and its competitors. According to the industry distribution chart, Initiator Pharma AS ranks #999999 out of 335 companies in the Biotechnology industry.
Is Initiator Pharma AS's EV-to-FCF too high?
Initiator Pharma AS's current EV-to-FCF is -3.86. Based on the distribution chart, Initiator Pharma AS ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Initiator Pharma AS has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Initiator Pharma AS's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Initiator Pharma AS ranks #999999 out of 335 companies for EV-to-FCF. This places Initiator Pharma AS in the lower half of its industry. The industry median EV-to-FCF is 15.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Initiator Pharma AS and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Initiator Pharma AS's current EV-to-FCF is -3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Initiator Pharma AS stock overvalued right now?
Initiator Pharma AS (OSTO:INIT) has a current EV-to-FCF of -3.86. The current EV-to-FCF is -3.86. Initiator Pharma AS's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Initiator Pharma AS (OSTO:INIT), the current EV-to-FCF is -3.86 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Initiator Pharma AS is a Danish clinical-stage life science company developing drugs that target key unmet medical needs within the central and peripheral nervous system. Its pipeline consists of three clinical programs: IP2018 and pudafensine for the treatment of erectile dysfunction of psychogenic and organic origin, respectively.
24GF Score
Get the complete analysis for OSTO:INIT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:INIT has been successfully added to your 
